1000TiPOPINION: A single-arm, open-label, phase IIIb study of olaparib maintenance monotherapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) and without germline BRCA mutations (non-gBRCAm).
- Resource Type
- Article
- Source
Annals of Oncology . 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.- Subject
- *
OVARIAN cancer - Language
- ISSN
- 0923-7534